GRALISE (gabapentin) tablets are indicated for
the management of postherpetic neuralgia (PHN).
PLEASE
GRALISE ME!
Help control the agony of PHN
*In a 10-week clinical trial, approximately one-third of GRALISE (gabapentin) patients achieved a 50%
reduction in pain from baseline and approximately one-half achieved a 30% reduction in pain with an
1800 mg once-daily dose (mean baseline pain score was 6.6 for GRALISE-treated patients).1,3
Indication and Usage
GRALISE (gabapentin) tablets are indicated for the management of
postherpetic neuralgia (PHN). GRALISE is not interchangeable with
other gabapentin products because of differing pharmacokinetic
profiles that affect the frequency of administration.
Important Safety Information
GRALISE is contraindicated in patients who have demonstrated
hypersensitivity to the drug or its ingredients.
Antiepileptic drugs (AEDs) including gabapentin, the active ingredient
in GRALISE, increase the risk of suicidal thoughts or behavior in
patients taking these drugs for any indication. Patients treated with
any AED for any indication should be monitored for the emergence or
worsening of depression, suicidal thoughts or behavior, and/or any
unusual changes in mood or behavior.
Across all GRALISE clinical trials, the other most common adverse
reactions (≥ 2%) are somnolence, headache, peripheral edema,
diarrhea, dry mouth, and nasopharyngitis.
Dosage adjustment of GRALISE is necessary in patients with impaired
renal function. GRALISE should not be administered in patients with
a creatinine clearance rate < 30 mL/min or in patients undergoing
hemodialysis.
Because every moment counts in PHN
Please see adjacent page for Brief Summary
of Prescribing Information. Full Prescribing
Information and Medication Guide are available
at GRALISE.com.
References:
1. GRALISE [prescribing information]. Newark, CA: Depomed Inc.;
December 2012. 2. Sang CN, et al. Gastroretentive gabapentin (G-GR)
formulation reduces intensity of pain associated with postherpetic
neuralgia (PHN). Clin J Pain. 2013;29:281-288. 3. Data on file,
Depomed Inc.
May 2013, Depomed Inc. All rights reserved. GRA-409-P.1